[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad Pontificia Comillas\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100608896","emotion-focused-therapy-in-the-treatment-of-prolonged-grief-disorder-100608896",false,"NCT07207512","Emotion-Focused Therapy in the Treatment of Prolonged Grief Disorder","Emotion-Focused Therapy in the Treatment of Prolonged Grief Disorder: Study Protocol for a Randomised Controlled Trial","EFT-PGD","Inclusion Criteria:\n\n* Adults (≥18 years).\n* Undergoing a grief process (including perinatal grief).\n* Meeting diagnostic criteria for Prolonged Grief Disorder (bereavement occurring six months or more prior to the loss; PG-13-R score ≥30).\n* Provision of informed consent.\n* Stable psychopharmacological medication for at least six weeks prior to therapy onset, with physician approval to maintain stability during the intervention.\n\nExclusion Criteria:\n\n* Concurrent psychological treatment\n* Bereavement occurring less than six months prior to the loss\n* Substance abuse\n* Eating disorder\n* Psychosis;\n* Organic brain syndrome\n* Suicide risk\n* Risk of harm to others.","ALL","18 Years",{"count":20,"type":21},128,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if Emotion-Focused Therapy (EFT) works to reduce symptoms of Prolonged Grief Disorder (PGD) in adults. PGD happens when the pain of losing a loved one lasts a long time and causes serious problems in daily life.\n\n* The main questions this study aims to answer are:\n\n  1. Does EFT lower grief symptoms in adults with PGD?\n  2. Does EFT also help with related problems, such as anxiety, depression, trauma, and overall distress?\n* Who can take part:\n\nAdults (18 years or older) who lost a loved one at least 6 months ago and meet the criteria for PGD.\n\n\\- What will happen in the study:\n\nParticipants will be randomly assigned to one of two groups:\n\n1. EFT group: 8 to 10 weekly, face-to-face therapy sessions with a trained therapist.\n2. Self-help group: 10 weekly self-help exercises based on EFT, completed on their own.\n\n   * All participants will complete questionnaires on grief, mood, and well-being before starting, during the study, at the end of treatment (12 weeks), and again at 5 months and 12 months after starting.\n   * In the EFT group, the therapeutic relationship will also be measured during sessions 3 and 8.\n   * Why this study is important:\n\nMost current treatments for grief are based on cognitive-behavioral therapy, but not everyone benefits from them. EFT is a promising therapy that focuses on emotions and has shown positive results for other mental health problems. This trial will test if EFT can be an effective treatment for people struggling with prolonged grief.",[27],"Prolonged Grief Disorder (PGD)",[29,30,31,32,33,34,35,36,37,38],"grief","bereavement","prolonged grief disorder","grief with complications","Emotion-Focused Therapy","PGD","Randomized Controlled Trial","RCT","study protocol","Treatment Effectiveness","NOT_YET_RECRUITING","2025-11-26",{"date":42,"type":43},"2025-12-04","ACTUAL",{"date":45,"type":21},"2026-09-01",{"date":47,"type":21},"2027-12-01",{"name":49,"class":50},"Universidad Pontificia Comillas","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":5},"100571994","ovs-breast-ovarian-suppression-in-breast-cancer-interventions-100571994","NCT06727487","OvS Breast: Ovarian Suppression in Breast Cancer Interventions","OvS Breast: ENBI Project, Ovarian Suppression in Breast Cancer: Exercise, Nutrition and Behavioural Intervention Project","ENBI","Inclusion Criteria:\n\n* Women who have reached the age of majority and up to 45 years of age.\n* Premenopausal status is defined clinically as a patient who maintains menstruation prior to the start of chemotherapy treatment if this has taken place.\n* Confirmed histological diagnosis of infiltrating breast carcinoma with expression of ER and\u002For RP stage I to III.\n* Loco-regional treatment with surgery and radiotherapy, if any, completed.\n* Adjuvant treatment with drugs that suppress ovarian function (aLHRH) is ongoing and expected to be maintained for at least 4 months at the beginning of the study.\n* Functional status according to the Eastern Cooperative Oncology Group (ECOG) scale 0-1.\n* Ability to understand and agree to the Informed Consent in writing.\n\nExclusion Criteria:\n\n* Presence of medical contraindications to perform physical exercise.\n* Presence of any of the American Thoracic Society (ATS) criteria to perform a cardiovascular capacity test.\n* Presence of active neoplastic disease: metastatic breast cancer or other active tumor diseases.\n* Pregnancy or breastfeeding.\n* Alcohol or other drug abuse (excluding smoking).","FEMALE","45 Years",{"count":63,"type":21},30,[24],"The goal of this clinical trial is to compare a combined intervention based on physical exercise, nutritional control, and individualized psycho-oncological support can achieve weight control and maintain adequate body composition in premenopausal women with localized BC with ER and\u002For PR expression who receive aLHRH in combination with TAM or AI as part of adjuvant treatment.\n\nThe study's primary objectives are to evaluate the impact of the combined intervention on weight reduction and favorable modification of body composition in terms of reduction in body fat and increase in lean mass.\n\nThe secondary objectives aim to evaluate the impact of the combined intervention program on CRF, heart rate (HR), capillary lactate levels, upper and lower body strength, physical functionality, and patient-reported outcomes (PROs). (exercise level, asthenia, self-perception, anxiety and depression), blood count and biochemistry values that could be modified, nutritional situation, and side effects of treatments.",[67],"Breast Neoplasms",[69,70,71,72],"Physical Exercise","Nutritional advice","Psico-oncological support","Patient Report Outcomes","RECRUITING","2024-12-06",{"date":76,"type":43},"2024-12-11",{"date":78,"type":43},"2024-11-15",{"date":80,"type":21},"2025-12-15",{"name":49,"class":50},""]